Host MHC class II+ antigen-presentirig cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions

被引:75
作者
Chakraverty, Ronjon [1 ]
Eom, Hyeon-Seok [1 ]
Sachs, Jessica [1 ]
Buchli, Jennifer [1 ]
Cotter, Pete [1 ]
Hsu, Richard [1 ]
Zhao, Guiling [1 ]
Sykes, Megan [1 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Bone Marrow Transplantat Sect,Transplantat Biol R, Boston, MA 02129 USA
关键词
D O I
10.1182/blood-2006-03-007427
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Following bone marrow transplantation, delayed donor leukocyte infusions (DLIs) can induce graft-versus-leukemia (GVL) effects without graft-versus-host disease (GVHD). These antitumor responses are maximized by the presence of host hematopoietic antigen-presenting cells (APCs) at the time of DLI. Using a tumor-protection model, we demonstrate here that GVIL activity following administration of DLIs to established mixed chimeras is dependent primarily on reactivity to allogeneic MHC antigens rather than minor histocompatibility or tumor-associated antigens. CD8(+) T-cell-dependent GVL responses against an MHC class II-negative tumor following delayed DLI require CD4(+) T-cell help and are reduced significantly when host APCs lack MHC class II expression. CD4(+) T cells primed by host APCs were required for maximal expansion of graft-versus-host reactive CD8(+) T cells but not their synthesis of IFN-gamma. In contrast, the GVL requirement for CD4(+) T-cell help was bypassed almost completely when DLI was administered to freshly irradiated recipients, indicating that the host environment is a major factor influencing the cellular mechanisms of GVL.
引用
收藏
页码:2106 / 2113
页数:8
相关论文
共 42 条
[21]   Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice [J].
Maury, S ;
Salomon, B ;
Klatzmann, D ;
Cohen, JL .
BLOOD, 2001, 98 (10) :3156-3158
[22]   Cutting edge: Naive T cells masquerading as memory cells [J].
Murali-Krishna, K ;
Ahmed, R .
JOURNAL OF IMMUNOLOGY, 2000, 165 (04) :1733-1737
[23]   Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells [J].
Pasare, C ;
Medzhitov, R .
SCIENCE, 2003, 299 (5609) :1033-1036
[24]   IMMUNODOMINANT MINOR HISTOCOMPATIBILITY ANTIGENS EXPRESSED BY MOUSE LEUKEMIC-CELLS CAN SERVE AS EFFECTIVE TARGETS FOR T-CELL IMMUNOTHERAPY [J].
PION, S ;
FONTAINE, P ;
BARON, C ;
GYGER, M ;
PERREAULT, C .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1561-1568
[25]   A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses [J].
Reddy, P ;
Maeda, Y ;
Liu, C ;
Krijanovski, OI ;
Korngold, R ;
Ferrara, JLM .
NATURE MEDICINE, 2005, 11 (11) :1244-1249
[26]   Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project [J].
Rimsza, LM ;
Roberts, RA ;
Miller, TP ;
Unger, JM ;
LeBlanc, M ;
Braziel, RM ;
Weisenberger, DD ;
Chan, WC ;
Muller-Hermelink, HK ;
Jaffe, ES ;
Gascoyne, RD ;
Campo, E ;
Fuchs, DA ;
Spier, CM ;
Fisher, RI ;
Delabie, J ;
Rosenwald, A ;
Staudt, LM ;
Grogan, TM .
BLOOD, 2004, 103 (11) :4251-4258
[27]   POSITIVE AND NEGATIVE SELECTION OF AN ANTIGEN RECEPTOR ON T-CELLS IN TRANSGENIC MICE [J].
SHA, WC ;
NELSON, CA ;
NEWBERRY, RD ;
KRANZ, DM ;
RUSSELL, JH ;
LOH, DY .
NATURE, 1988, 336 (6194) :73-76
[28]   Prevention of graft versus host disease by inactivation of host antigen-presenting cells [J].
Shlomchik, WD ;
Couzens, MS ;
Tang, CB ;
McNiff, J ;
Robert, ME ;
Liu, JL ;
Shlomchik, MJ ;
Emerson, SG .
SCIENCE, 1999, 285 (5426) :412-415
[29]   Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion [J].
Soiffer, RJ ;
Alyea, ER ;
Hochberg, E ;
Wu, C ;
Canning, C ;
Parikh, B ;
Zahrieh, D ;
Webb, I ;
Antin, J ;
Ritz, J .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (11) :625-632
[30]   Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies [J].
Spitzer, TR ;
McAfee, SL ;
Dey, BR ;
Colby, C ;
Hope, J ;
Grossberg, H ;
Preffer, F ;
Shaffer, J ;
Alexander, SI ;
Sachs, DH ;
Sykes, M .
TRANSPLANTATION, 2003, 75 (10) :1748-1751